Opaleye Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Opaleye Management’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-597,500	Closed	-$5.57M	–	54
2023 Q2	$5.57M	Buy	597,500 +109,400	+22%	+$1.08M	1.33%	21
2023 Q1	$4.33M	Sell	488,100 -46,900	-9%	-$460K	1.3%	26
2022 Q4	$2.66M	Buy	535,000 +314,350	+142%	+$1.84M	0.93%	31
2022 Q3	$1.28M	Buy	220,650 +188,350	+583%	+$1.33M	0.53%	27
2022 Q2	$179K	Buy	+32,300	New	+$267K	0.08%	45

Other funds holding THRX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Opaleye Management's THRX Position: Q3 2023 in Review

Opaleye Management sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q3 2023, closing a stake of 597,500 shares — an estimated $5.57M sold.

Opaleye Management first reported a position in THRX in Q2 2022 and held it in 5 quarters. The position peaked at $5.57M in Q2 2023. 63 funds tracked by Wall St. Rank hold THRX as of Q3 2023.

Opaleye Management reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Opaleye Management sold 597,500 Theseus Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $5.57M.
Opaleye Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
Opaleye Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $5.57M in Q2 2023.
63 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Opaleye Management's 13F filing for Q3 2023, filed 15 Nov 2023.